University of Toronto, Department of Immunology, Toronto, Ontario, Canada.
University of Toronto, Department of Immunology, Toronto, Ontario, Canada.
Semin Immunol. 2017 Aug;32:3-13. doi: 10.1016/j.smim.2017.04.003. Epub 2017 May 2.
Dysbiosis of gut microbiota occurs in many human chronic immune-mediated diseases, such as inflammatory bowel disease (IBD) and colitis-associated colorectal cancer (CAC). Reciprocally, uncontrolled immune responses, that may or may not be induced by dysbiosis, are central to the development of IBD and CAC. There has been a surge of interest in investigating the relationship between microbiota, inflammation and CAC. In this review, we discuss recent findings related to gut microbiota and chronic immune-mediated diseases, such as IBD and CAC. Moreover, the molecular mechanisms underlying the roles of chronic inflammation in CAC are examined. Finally, we discuss the development of novel microbiota-based therapeutics for IBD and colorectal cancer.
肠道微生物群落失调发生在许多人类慢性免疫介导性疾病中，如炎症性肠病（IBD）和结肠炎相关结直肠癌（CAC）。相反，不受控制的免疫反应，可能是也可能不是由微生物群落失调引起的，是 IBD 和 CAC 发展的核心。人们对研究微生物群、炎症与 CAC 之间的关系产生了浓厚的兴趣。在这篇综述中，我们讨论了与肠道微生物群和慢性免疫介导性疾病（如 IBD 和 CAC）相关的最新发现。此外，还研究了慢性炎症在 CAC 中作用的分子机制。最后，我们讨论了基于微生物组的新型治疗方法在 IBD 和结直肠癌中的发展。
